Function of Ss-A/Ro ribonucleoprotein 60-ku subunit in multidrug resistance of gastric cancer
Quan-Li Han,Jie Ding,Long-Fang Zhang,Xin Wang,Chang-Cun Guo,Tai-Dong Qiao,Xue-Yong Zhang,Dai-Ming Fan
DOI: https://doi.org/10.3969/j.issn.1009-3079.2006.03.003
2006-01-01
World Chinese Journal of Digestology
Abstract:AIM: To investigate the possible function of Ss-A/Ro ribonucleoprotein 60-ku subunit (Ro 60) in the multidrug resistance (MDR) of gastric cancer cell line. METHODS: The Ro 60 encoding gene was cloned using reverse transcription polymerase chain reaction (RT-PCR). DNA recombination technique was used to construct Ro 60 sense eukaryotic expression vector, and then the product was transfected into SGC7901 cells by LipofectamineTM 2000. Drug susceptibility in the chemotherapy was analyzed by MTT assay, and IC50 value of gastric cancer cells to chemotherapy drugs was calculated. The intracellular accumulation of adriamycin in gastric cancer cells was measured using fluorescence-activated cell sorting. RESULTS: The expression level of Ro 60 in SGC7901 was increased after transfection with sense genes. In vitro drug sensitivity assay showed that SGC7901 cells transfected with Ro 60 genes significantly decreased sensitivity to vincristine (IC50: 2.28±0.11 mg/L vs 0.45±0.04, 0.65±0.05 mg/L, P < 0.01), 5-fluorouracil (5-FU) (IC50: 2.89±0.14 mg/L vs 0.61±0.21, 0.90±0.11 mg/L, P < 0.01), mitomycin (IC50: 1.92±0.03 mg/L vs 0.54±0.03, 0.75±0.21 mg/L, P < 0.01), cisplatin (IC50: 1.41±0.06 mg/L vs 0.45±0.03, 0.54±0.03 mg/L, P < 0.01) and adriamycin (IC50: 0.28±0.03 mg/L vs 0.14±0.01,0.14±0.01 mg/L, P < 0.01), when compared with SGC7901 and SGC7901-pcDNA3.1 cells. The intracellular accumulation of adriamycin in the cells transfected with Ro 60 gene was markedly decreased in comparison with that in SGC7901 and SGC7901-pcDNA3.1 cells (56.30±2.49 mg/L vs 92.83±3.63, 87.38±2.94 mg/L, P< 0.01). CONCLUSION: SGC7901 cells transfected with Ro 60 sense genes show some competence of MDR. Ro 60 may play a certain role in the MDR of gastric cancer.